key: cord-0989938-ywicchap authors: Dicpinigaitis, Peter V. title: LUNG Year in Review: 2021 date: 2022-01-18 journal: Lung DOI: 10.1007/s00408-022-00510-9 sha: 751dfd22579aed369356cd8a8f516f2608166462 doc_id: 989938 cord_uid: ywicchap nan The end of 2021 marked the conclusion of the second year of service of the current Editor-in-Chief and Editorial Board of LUNG. Positive results achieved in 2020 were continued in 2021, as evidenced by an increasing number of article downloads and a rising journal impact factor. High-quality manuscripts were submitted by authors worldwide, resulting in an article acceptance rate of under 15%. In keeping with initially stated goals [1] , we published ten State-of-the Art review articles in our six issues of 2021 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . State-of-the-Art reviews are comprehensive, up-todate reviews on specific topics contributed by experts in the field. Such articles are typically invited, however, outstanding, unsolicited reviews are also considered. Among ongoing efforts at LUNG is the enhancement of critical care content of the journal. To that end, we were pleased to publish a number of high-quality articles, including studies examining ventilator-induced lung injury [12] , acute respiratory distress syndrome (ARDS) [13, 14] , and weaning from non-invasive ventilation [15] . The year 2021 marked the second year of the COVID-19 pandemic. Although the volume was not nearly as high as in 2020, SARS-CoV-2-related submissions in 2021 were many, but acceptances were few. In keeping with our policy of 2020 [16] [17] [18] [19] , accepted articles in 2021 were limited to those providing new and useful insights into COVID-19. Such contributions included a review of COVID-19 in children with asthma [2] , post-COVID-19 chronic cough and other symptom burden [20] [21] [22] , as well as evaluations of therapeutic interventions [23, 24] and comparison of mortality compared with seasonal influenza [25] . In keeping with historical precedent, LUNG continues to give prominent attention to the important, and recently very active, field of cough. Indeed, 2022 promises to be a landmark year in the cough space, as we anticipate the approval of the first-ever drug indicated for the treatment of refractory chronic cough [26, 27] . Cough-related articles published in 2021 examined post-COVID-19 cough [20, 22] , clinical antitussive drug trials [28] , and the importance of the placebo response [7] , relevance of speech-language pathology interventions in chronic cough therapy [29, 30], cough monitoring [31], cough mechanisms, and diagnostic evaluation [32] [33] [34] [35] [36] [37] [38] [39] . The field of lung cancer investigation continues to grow and represents a major focus in pulmonary medicine. LUNG participated in the dissemination of evolving knowledge in this area by publishing a State-of-the-Art review on new developments in the diagnosis and management of smallcell lung cancer [10] in addition to a collection of articles examining lung cancer evaluation, therapy, complications, and survival [40] [41] [42] [43] [44] [45] [46] [47] [48] . Many contributions in the ever-expanding area of interventional pulmonology were received in 2021. Interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) remain subjects of active and increasing investigation. Reflecting this ongoing scientific production, LUNG published two relevant State-of-the-Art reviews [3, 8] [68] . Obstructive airways disease was again well represented in the journal. An eclectic collection of published articles examined various aspects of chronic obstructive pulmonary disease and asthma [2, 11, 15, 31, 55, 64, [69] [70] [71] [72] [73] . The growing field of obstructive sleep apnea syndrome (OSAS) received due attention within the pages of LUNG in 2021. In addition to a State-of-the-Art review on evaluation and management of adults with OSAS [4] , clinical studies reported on associated comorbidities [74] and biomarkers [75] . Additional contributions included investigations of various aspects of pulmonary vascular disease [76, 77] , lung transplantation [78, 79] , pulmonary function testing [80] , aspiration pneumonia [81] , and vaping-associated conditions [82] . Our goal of featuring quality studies in pediatric pulmonology was fulfilled in 2021. In addition to a State-of-the-Art review on COVID-19 in children with asthma [2] , investigations in cystic fibrosis [83, 84] and pediatric cough [37] appeared in our pages. We continue to invite high-quality submissions in the field of pediatric respiratory medicine. The vital area of translational research was well represented in the form of preclinical investigations examining a range of clinically relevant topics, including a State-ofthe-Art review on non-invasive measurement of pulmonary function [6] , as well as studies involving β-2 adrenergic receptors [85, 86] , pulmonary fibroblast cell growth [87] , and hyperoxia-induced alveolar epithelial cell injury [88] . Throughout 2021, the editorial team at LUNG worked in earnest to build on successes achieved in 2020. We strive to maintain a positive trajectory in the enhancement of the quality and impact of our journal. To that end, we will remain dependent on our colleagues worldwide, working in the laboratory and in the clinic, to contribute their quality work to LUNG. LUNG year in review: 2020 COVID-19 in children with asthma Tobacco worker's lung: a neglected subtype of hypersensitivity pneumonitis Evaluation and management of adults with obstructive sleep apnea syndrome Diffuse alveolar hemorrhage in cardiac diseases Noninvasive measurement of pulmonary function in experimental mouse models of airway disease Eccles R (2021) Placebo and side effects confound clinical trials on new antitussives Inhalational constrictive bronchiolitis: the evolution of our understanding of this disease Twenty-year reflection on the impact of World Trade Center exposure on pulmonary outcomes in Fire Department of the City of New York (FDNY) rescue and recovery workers Update 2021: management of small cell lung cancer Eosinophilic chronic obstructive pulmonary disease Inhibition of MicroRNA-214 alleviates lung injury and inflammation via increasing FGFR1 expression in ventilator-induced lung injury Timing of ARDS resolution (TARU): a pragmatic clinical assessment of ARDS resolution in the ICU Prevalence and outcome of acute respiratory distress syndrome in traumatic brain injury: a systematic review and meta-analysis Predictors of successful weaning from noninvasive ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease: a single-center retrospective cohort study Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19? Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARS-CoV-2 ACE2: the major cell entry receptor for SARS-CoV-2 Is there (will there be) a post-COVID-19 chronic cough Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Post-viral anosmia (loss of sensation of smell) did not begin with COVID-19! Lung Prevalence of post-COVID-19 cough one year after SARS-CoV-2 infection: a multicenter study Tocilizumab in hospitalized patients with COVID-19: a meta analysis of randomized controlled trials Use of thiols in the treatment of COVID-19: current evidence Comparison of deaths from COVID-19 and seasonal influenza in the USA (Letter to the Editor) Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough Coming soon: the first-ever drug(s) for refractory chronic cough Characterization of patients with refractory or unexplained chronic cough participating in a phase 2 clinical trial of the P2X3-receptor antagonist gefapixant Clinical characteristics of sarcoidosis patients with self-reported lymphoma: a US nationwide registry study Irritant-induced asthma caused by aerotoxic syndrome The association between asthma and risk of myasthenia gravis: a systematic review and meta-analysis Determinants and follow-up of lung function data from a predominantly First Nations cohort of adults referred to specialist respiratory outreach clinics in regional and remote Queensland Efficacy of high-flow nasal cannula oxygen therapy in patients with mild hypercapnia FIZZ2 as a biomarker for acute exacerbation of chronic obstructive pulmonary disease Influence of obstructive sleep apnea severity on coronary collateral recruitment during coronary occlusion Effects of continuous positive airway pressure on cell adhesion molecules in patients with obstructive sleep apnea: a meta-analysis Excipient-induced pulmonary vascular disease: an underrecognized and deadly complication of opioid addiction Effect of balloon pulmonary angioplasty on homogenization of lung perfusion blood volume by dual-energy computed tomography in patients with chronic thromboembolic pulmonary hypertension Utilization of quantitative computed tomography assessment to identify bronchiolitis obliterans syndrome after single lung transplantation The role of galectins in chronic lung allograft dysfunction Pulmonary function testing in patients with tracheostomies: feasibility and technical considerations Prevalence and severity of dysphagia using videofluoroscopic swallowing study in patients with aspiration pneumonia Vaping associated pulmonary nontuberculous mycobacteria Abnormal lung clearance index in cystic fibrosis children with normal FEV 1 and single-breath nitrogen washout test How many maneuvers should we do for maximal inspiratory and expiratory muscle pressure testing in children: a retrospective review in children with cystic fibrosis Spatiotemporal changes in the gene expression spectrum of the β2 adrenergic receptor signaling pathway in the lungs of Rhesus monkeys 2 -adrenoceptor activation stimulates IL-6 production via PKA, ERK1/2, Src, and betaarrestin 2 signaling pathways in human bronchial epithelia Analyzing the effect of vitronectin on cell growth and mesenchymal-epithelial transition of pulmonary fibroblast cells ETS1 ameliorates hyperoxia-induced alveolar epithelial cell injury by regulating the TGM2-mediated Wnt/β-catenin pathway Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations